$0.311
-0.135 (-43.30%)Al cierre
- High
- 0.555
- Open
- 0.550
- VWAP
- 0.38
- Vol
- 12.45M
- Mkt Cap
- 3.02M
- Low
- 0.270
- Amount
- 4.72M
- EV/EBITDA, TTM
- 0.00
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Métricas de valoración
Cronología de eventos
Noticias
9.505-13seekingalphaZyVersa Therapeutics Reports Financial Strain in Q1 Earnings
8.505-13NewsfilterZyVersa Advances Innovative Drug Development for Inflammatory and Renal Diseases
- 9.503-31seekingalpha
ZyVersa Therapeutics Reports FY Financials
- 7.503-31Newsfilter
ZyVersa Advances Innovative Drug Development for Inflammatory and Renal Diseases
- 9.511-19Newsfilter
ZyVersa Therapeutics Announces Financial Results for Q3 2025
ZVSA FAQ — answered by Alphio AI
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.